ROSE Data · Mauritania
67.9%
Diagnoses at stage III or IV (BRCA study)
44.5% stage III + 23.4% stage IV, 137 patients
Source: Screening of BRCA1/2 variants in Mauritanian breast cancer patients (Mohamed Brahim S. et al.) — BMC Cancer, 2022
Diagnoses at stage III or IV (BRCA study)
44.5% stage III + 23.4% stage IV, 137 patients
Source: Screening of BRCA1/2 variants in Mauritanian breast cancer patients (Mohamed Brahim S. et al.) — BMC Cancer, 2022